SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Jul 24, 2018
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: July 24, 2018 · CIK: 0001513525 · Accession: 0001213900-18-009574
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220368
Letter
VIA EDGAR Division of Corporation Finance Attention: Suzanne Hayes, Assistant Director Office of Healthcare & Insurance Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-220368
Dear Ms. Hayes:
Adial Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1, as amended (File No. 333-220368), be accelerated by the U.S. Securities and Exchange Commission to Thursday, July 26, 2018 at 5:00 p.m., New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes its legal counsel, Patrick Egan and/or Leslie Marlow of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Egan at (914) 557-5574 or Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
Adial Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Adial Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
July 24, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Office of Healthcare & Insurance
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No. 333-220368
Dear Ms. Hayes:
Adial Pharmaceuticals,
Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on
Form S-1, as amended (File No. 333-220368), be accelerated by the U.S. Securities and Exchange Commission to Thursday,
July 26, 2018 at 5:00 p.m., New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby
authorizes its legal counsel, Patrick Egan and/or Leslie Marlow of Gracin & Marlow, LLP, to orally modify or withdraw this
request for acceleration. Please contact Mr. Egan at (914) 557-5574 or Ms. Marlow at (516) 496-2223 or (212) 907-6457 with
any questions you may have concerning this request, and please notify either of them when this request for acceleration has been
granted.
Very truly yours,
Adial Pharmaceuticals, Inc.
By:
/s/ William B. Stilley, III
Name: William B. Stilley, III
Title: Chief Executive Officer
cc:
Joseph Truluck
Chief Financial Officer, Adial Pharmaceuticals, Inc.